tiprankstipranks
Analyst Profile
Followed by 67 other investors
.
George Zavoico

George Zavoico

B.Riley Financial
Wall Street Analyst
Ranked #1,011 out of 8,047 Analysts on TipRanks (#1,719 out of 21,521 overall experts)

Success Rate

43%
55 out of 128 Profitable Transactions

Average Return

14.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied George Zavoico's ratings since 2011 and opened each position for the duration of 1 Year:
42.97% of your transactions would have been profitable with an average return of 14.7%

Stock Rating Distribution

171Ratings
93.57% Buy
6.43% Hold
0.00% Sell
Distribution of George Zavoico's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Novavax
(NVAX)
Rating Type:Buy
Dates:Sep 16, 2019 - Sep 16, 2020
Gain:800.00%
The most profitable rating made by George Zavoico

George Zavoico's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Epirus Biopharma
Buy
Initiated
$4.00
(399999900.00% Upside)
0%
-46.50%
1
Genomic Health
Hold
Reiterated
0.00%
1
ACADIA Pharmaceuticals
Hold
Downgraded
$20.00
(21.95% Upside)
100%
+55.60%
2
Madrigal Pharmaceuticals
Buy
Reiterated
$10.00
(-86.36% Downside)
0%
-29.23%
3
Xoma
Buy
Reiterated
$7.00
(-65.14% Downside)
0%
-80.80%
1
Avid Bioservices
Buy
Reiterated
$3.50
(-82.22% Downside)
0%
-27.90%
3
Oncotelic Therapeutics
Buy
Reiterated
$6.50
(7547.06% Upside)
0%
-61.40%
4
Aeterna Zentaris
Buy
Reiterated
$80.00
(1503.21% Upside)
0%
-78.40%
1
Cerus
Buy
Reiterated
$10.00
(91.20% Upside)
100%
+31.03%
6
Keryx Biopharma
Buy
Reiterated
0%
-70.40%
1
List of latest recommendations made by George Zavoico. Click to expand and see George Zavoico's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More